Xp11.2 基因轉位腎細胞癌-中榮總經驗分享
廖博崎、賀昊中、裘坤元、程千里、李建儀、歐宴泉、王賢祥* 
臺中榮總外科部泌尿外科*
Xp11.2 translocation renal cell carcinoma - experiences of VGHTC
Po-Chi Liao, Hao-Chung Ho, Kun-Yuan Chiu, Chen-Li Cheng, Jian-Ri Li,
Yen-Chuan Ou, Shian-Shiang Wang *
Division of Urology, Department of Surgery, Taichung Veterans General Hospital*
 
Purpose: Xp 11.2 translocation renal cell carcinoma (RCC) is a rare subtype of renal tumors and is first classified in the 2004 WHO renal tumor classification. This subtype affects children more than adult and is believed more aggressive than other subtypes. We reviewed the clinical course of the patients with Xp 11.2 translocation RCC in our institution.
Materials and Methods: There were four patients diagnosed as Xp 11.2 translocation from 2011 to 2017 in Taichung Veterans General Hospital. Initial presentation of clinical symptoms, image findings, treatment and outcome were analyzed.
Results: In our study, there were 3 women and one man. The mean age at diagnosis was 47.5 years old. Two patients presented with painless hematuria as initial symptom, one with flank soreness and the other one was incidentally found by abdominal sonography. The tumors were all located in the right kidney and were measured with mean diameter of 4.8cm. Two of our patients presented with lymph node metastasis at time of diagnosis, and one eventually developed carcinomatosis and multiple lung metastasis. One patient was diagnosed as stage I, two patients with stage III and the other one with stage IV (liver metastasis) disease. Treatment included two laparoscopic radical nephrectomy, one open nephrectomy and one open partial nephrectomy. In three of our patients, one received Interferon-Alfa-2a injection for one year, one received oral sunitinib treatment for one year and one was included in clinical trial with Torisel one month. Three patients showed no evidence of disease recurrence during mean follow-up of 3.3 years. One patient died after 7 months of follow up due to cancer progression. One patient with liver metastasis at diagnosis received radical nephrectomy, liver tumor resection and 3 months sunitinib treatment and remained no evidence of tumor recurrence after three years follow up.
Conclusions: Xp11.2 translocation RCC is believed to more aggressive than other subtypes of RCC. Radical operation seems to provide better cancer control. Systemic treatment for this subtype tumor remains to be determined.
 
    位置
    資料夾名稱
    摘要
    發表人
    TUA秘書處
    單位
    台灣泌尿科醫學會
    建立
    2017-06-01 11:15:28
    最近修訂
    2017-06-01 11:20:54
    更多